Impact of age and sex on the efficacy of fremanezumab in patients with difficult-to-treat migraine: results of the randomized, placebo-controlled, phase 3b FOCUS study

被引：0
|
作者：
Antoinette MaassenVanDenBrink
Gisela M. Terwindt
Joshua M. Cohen
Steve Barash
Verena Ramirez Campos
Maja Galic
Xiaoping Ning
Mikko Kärppä
机构：
[1] Erasmus University Medical Center Rotterdam,Division of Pharmacology and Vascular Medicine, Department of Internal Medicine
[2] Leiden University Medical Center,Department of Neurology
[3] Teva Pharmaceutical Products R&D,Research Unit of Clinical Neuroscience
[4] Inc.,undefined
[5] Teva Pharmaceuticals Europe B.V.,undefined
[6] University of Oulu and Medical Research Center,undefined
[7] Oulu University Hospital,undefined
来源：
The Journal of Headache and Pain | 2021年 / 22卷
关键词：
Fremanezumab; Calcitonin gene-related peptide; Age; Sex; Migraine;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Impact of age and sex on the efficacy of fremanezumab in patients with difficult-to-treat migraine: results of the randomized, placebo-controlled, phase 3b FOCUS study
    MaassenVanDenBrink, Antoinette
    Terwindt, Gisela M.
    Cohen, Joshua M.
    Barash, Steve
    Campos, Verena Ramirez
    Galic, Maja
    Ning, Xiaoping
    Karppa, Mikko
    JOURNAL OF HEADACHE AND PAIN, 2021, 22 (01):
  • [2] Efficacy and safety of fremanezumab in patients with obesity and difficult-to-treat migraine: Subgroup analysis of the randomized, double-blind, phase 3b FOCUS study
    Torphy, B.
    Ortega, M.
    Krasenbaum, L. J.
    Ning, X.
    Seminerio, M. J.
    Lyras, L.
    Lengil, T.
    Akcicek, H.
    Janka, L.
    Smith, M.
    Holle-Lee, D.
    HEADACHE, 2022, 62 : 142 - 142
  • [3] Impact of age and sex on efficacy of fremanezumab in patients with migraine and documented inadequate response to 2-4 classes of migraine preventive treatments: results of the international, multicentre, randomised, placebo-controlled FOCUS study
    MaassenVanDenBrink, Antoinette
    Galic, Maja
    Cohen, Joshua M.
    Ning, Xiaoping
    Yang, Ronghua
    Ramirez-Campos, Verena
    JOURNAL OF HEADACHE AND PAIN, 2020, 21 (SUPPL 1):
  • [4] Efficacy of Fremanezumab Treatment in Patients ≥60 Years of Age With Episodic or Chronic Migraine: Pooled Results of 3 Randomized, Double-Blind, Placebo-controlled Phase 3 Studies
    Nahas, S. J.
    Ning, X.
    Cohen, J. M.
    Yang, R.
    Ramirez-Campos, V
    Silberstein, S. D.
    HEADACHE, 2020, 60 : 14 - 15
  • [5] Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial
    Ferrari, Michel D.
    Diener, Hans Christoph
    Ning, Xiaoping
    Galic, Maja
    Cohen, Joshua M.
    Yang, Ronghua
    Mueller, Matthias
    Ahn, Andrew H.
    Schwartz, Yael Carmeli
    Grozinski-Wolff, Melissa
    Janka, Lindsay
    Ashina, Messoud
    LANCET, 2019, 394 (10203): : 1030 - 1040
  • [6] Efficacy of Fremanezumab in Male Patients With Migraine and Documented Inadequate Response to 2-4 Classes of Migraine Preventive Medication Classes: Results of the Randomized, Placebo-controlled FOCUS Study
    MaassenVanDenBrink, Antoinette
    Terwindt, Gisela
    Cohen, Joshua
    Yang, Ronghua
    Ramirez-Campos, Verena
    Galic, Maja
    Ning, Xiaoping
    Karppa, Mikko
    NEUROLOGY, 2020, 94 (15)
  • [7] Efficacy and Safety of Fremanezumab in Patients with Migraine and Documented Inadequate Response to 2-4 Classes of Migraine Preventive Medications: Results of the Multicenter, Randomized, Placebo-controlled FOCUS Study
    Ferrari, M. D.
    Diener, H.
    Ning, X.
    Galic, M.
    Cohen, J. M.
    Yang, R.
    Ashina, M.
    HEADACHE, 2019, 59 : 93 - 94
  • [8] Impact of Fremanezumab on Disability Severity in Patients With Episodic and Chronic Migraine: Pooled Results of 3 Randomized, Double-blind, Placebo-controlled Phase 3 Studies
    Nagy, Abraham J.
    McAllister, Peter
    Cohen, Joshua M.
    Ning, Xiaoping
    Campos, Verena Ramirez
    Du, Evelyn
    Ashina, Messoud
    NEUROLOGY, 2021, 96 (15)
  • [9] IMPACT OF FREMANEZUMAB ON DISABILITY SEVERITY IN PATIENTS WITH EPISODIC AND CHRONIC MIGRAINE: POOLED RESULTS OF 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDIES
    Nagy, Abraham J.
    McAllister, Peter
    Cohen, Joshua M.
    Ning, Xiaoping
    Campos, Verena Ramirez
    Du, Evelyn
    Ashina, Messoud
    CEPHALALGIA, 2020, 40 : 93 - 94
  • [10] Efficacy of Fremanezumab in Patients with Migraine and Documented Inadequate Response to 3 or 4 Migraine Preventive Medication Classes and Medication Overuse in the International, Multicenter, Randomized, Placebo-Controlled FOCUS Study
    Pazdera, Ladislav
    Ning, Xiaoping
    Campos, Verena Ramirez
    Yang, Ronghua
    Carr, Karen
    Cohen, Joshua M.
    ANNALS OF NEUROLOGY, 2020, 88 : S155 - S156
12345